Privium Fund Management B.V. Vertex Pharmaceuticals Inc Transaction History

Privium Fund Management B.V.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$343.0 - $410.68 $2.15 Million - $2.58 Million	-6,279 Reduced 29.35%	15,116 $6.15 Million
Q3 2023 Nov 06, 2023	SELL	$338.18 - $362.46 $3.22 Million - $3.45 Million	-9,515 Reduced 30.78%	21,395 $7.44 Million
Q2 2023 Jul 25, 2023	SELL	$314.42 - $351.91 $490,495 - $548,979	-1,560 Reduced 4.8%	30,910 $10.9 Million
Q1 2023 May 03, 2023	SELL	$283.23 - $323.1 $803,523 - $916,634	-2,837 Reduced 8.04%	32,470 $10.2 Million
Q4 2022 Feb 02, 2023	BUY	$285.76 - $321.48 $1.95 Million - $2.19 Million	6,807 Added 23.88%	35,307 $10.2 Million
Q3 2022 Nov 03, 2022	BUY	$273.83 - $305.53 $136,915 - $152,765	500 Added 1.79%	28,500 $8.35 Million
Q1 2022 May 10, 2022	SELL	$221.42 - $260.97 $664,260 - $782,910	-3,000 Reduced 9.68%	28,000 $7.31 Million
Q4 2021 Feb 09, 2022	BUY	$177.01 - $223.45 $5.49 Million - $6.93 Million	31,000 New	31,000 $6.9 Million

1,716

225M

1.19M

1.56M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Privium Fund Management B.V., based on Form 13F filings with the SEC.

Stay updated on Privium Fund Management B.V. with notifications on news.